<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Inherit Metab Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Inherit Metab Dis</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1573-2665</journal-id>
      <journal-id journal-id-type="publisher-id">JIMD</journal-id>
      <journal-title-group>
        <journal-title>Journal of Inherited Metabolic Disease</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0141-8955</issn>
      <issn pub-type="epub">1573-2665</issn>
      <publisher>
        <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
        <publisher-loc>Hoboken, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32160317</article-id>
      <article-id pub-id-type="pmc">7484123</article-id>
      <article-id pub-id-type="doi">10.1002/jimd.12232</article-id>
      <article-id pub-id-type="publisher-id">JIMD12232</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Original Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pathogenic variants in <styled-content style="fixed-case" toggle="no"><italic>SQOR</italic></styled-content> encoding sulfide:quinone oxidoreductase are a potentially treatable cause of Leigh disease</article-title>
        <alt-title alt-title-type="left-running-head">Friederich et al.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="jimd12232-cr-0001" contrib-type="author">
          <name>
            <surname>Friederich</surname>
            <given-names>Marisa W.</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="jimd12232-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0002" contrib-type="author">
          <name>
            <surname>Elias</surname>
            <given-names>Abdallah F.</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0003" contrib-type="author">
          <name>
            <surname>Kuster</surname>
            <given-names>Alice</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0004">
<sup>4</sup>
</xref>
          <xref ref-type="aff" rid="jimd12232-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0004" contrib-type="author">
          <name>
            <surname>Laugwitz</surname>
            <given-names>Lucia</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0005" contrib-type="author">
          <name>
            <surname>Larson</surname>
            <given-names>Austin A.</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0006" contrib-type="author">
          <name>
            <surname>Landry</surname>
            <given-names>Aaron P.</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0007">
<sup>7</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0007" contrib-type="author">
          <name>
            <surname>Ellwood&#x2010;Digel</surname>
            <given-names>Logan</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0008" contrib-type="author">
          <name>
            <surname>Mirsky</surname>
            <given-names>David M.</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0008">
<sup>8</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0009" contrib-type="author">
          <name>
            <surname>Dimmock</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0009">
<sup>9</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0010" contrib-type="author">
          <name>
            <surname>Haven</surname>
            <given-names>Jaclyn</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0011" contrib-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Hua</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0012" contrib-type="author">
          <name>
            <surname>MacLean</surname>
            <given-names>Kenneth N.</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0013" contrib-type="author">
          <name>
            <surname>Styren</surname>
            <given-names>Katie</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0014" contrib-type="author">
          <name>
            <surname>Schoof</surname>
            <given-names>Jonathan</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0015" contrib-type="author">
          <name>
            <surname>Goujon</surname>
            <given-names>Louise</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0004">
<sup>4</sup>
</xref>
          <xref ref-type="aff" rid="jimd12232-aff-0010">
<sup>10</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0016" contrib-type="author">
          <name>
            <surname>Lefrancois</surname>
            <given-names>Thomas</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0011">
<sup>11</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0017" contrib-type="author">
          <name>
            <surname>Friederich</surname>
            <given-names>Maike</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0018" contrib-type="author">
          <name>
            <surname>Coughlin</surname>
            <given-names>Curtis R.</given-names>
            <suffix>II</suffix>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0019" contrib-type="author">
          <name>
            <surname>Banerjee</surname>
            <given-names>Ruma</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0007">
<sup>7</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0020" contrib-type="author">
          <name>
            <surname>Haack</surname>
            <given-names>Tobias B.</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0005">
<sup>5</sup>
</xref>
          <xref ref-type="aff" rid="jimd12232-aff-0012">
<sup>12</sup>
</xref>
        </contrib>
        <contrib id="jimd12232-cr-0021" contrib-type="author" corresp="yes">
          <name>
            <surname>Van Hove</surname>
            <given-names>Johan L. K.</given-names>
          </name>
          <xref ref-type="aff" rid="jimd12232-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="jimd12232-aff-0002">
<sup>2</sup>
</xref>
          <address>
            <email>johan.vanhove@childrenscolorado.org</email>
          </address>
        </contrib>
      </contrib-group>
      <aff id="jimd12232-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Section of Clinical Genetics and Metabolism, Department of Pediatrics</named-content>
<institution>University of Colorado</institution>
<city>Aurora</city>
<named-content content-type="country-part">Colorado</named-content>
</aff>
      <aff id="jimd12232-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Pathology and Laboratory Medicine</named-content>
<institution>Children's Hospital Colorado</institution>
<city>Aurora</city>
<named-content content-type="country-part">Colorado</named-content>
</aff>
      <aff id="jimd12232-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Medical Genetics</named-content>
<institution>Shodair Children's Hospital</institution>
<city>Helena</city>
<named-content content-type="country-part">Montana</named-content>
</aff>
      <aff id="jimd12232-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Neurometabolism</named-content>
<institution>University Hospital of Nantes</institution>
<city>Nantes</city>
<country country="FR">France</country>
</aff>
      <aff id="jimd12232-aff-0005">
<label><sup>5</sup></label>
<institution>INRAE, UMR1280, PhAN, Nantes Universit&#xE9;</institution>
<city>Nantes</city>
<country country="FR">France</country>
</aff>
      <aff id="jimd12232-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Institut f&#xFC;r Medizinische Genetik und Angewandte Genomik</named-content>
<institution>Universit&#xE4;tsklinikum, University of T&#xFC;bingen</institution>
<city>T&#xFC;bingen</city>
<country country="DE">Germany</country>
</aff>
      <aff id="jimd12232-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Department of Biological Chemistry</named-content>
<institution>University of Michigan</institution>
<city>Ann Arbor</city>
<named-content content-type="country-part">Michigan</named-content>
</aff>
      <aff id="jimd12232-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>University of Colorado, and Children's Hospital Colorado</institution>
<city>Aurora</city>
<named-content content-type="country-part">Colorado</named-content>
</aff>
      <aff id="jimd12232-aff-0009">
<label><sup>9</sup></label>
<institution>Rady Children's Institute for Genomic Medicine</institution>
<city>San Diego</city>
<named-content content-type="country-part">California</named-content>
</aff>
      <aff id="jimd12232-aff-0010">
<label><sup>10</sup></label>
<named-content content-type="organisation-division">Service de G&#xE9;n&#xE9;tique Clinique</named-content>
<institution>University Hospital of Rennes</institution>
<city>Rennes</city>
<country country="FR">France</country>
</aff>
      <aff id="jimd12232-aff-0011">
<label><sup>11</sup></label>
<named-content content-type="organisation-division">Pediatric Radiology</named-content>
<institution>University Hospital of Nantes</institution>
<city>Nantes</city>
<country country="FR">France</country>
</aff>
      <aff id="jimd12232-aff-0012">
<label><sup>12</sup></label>
<named-content content-type="organisation-division">Centre for Rare Diseases</named-content>
<institution>University of T&#xFC;bingen</institution>
<city>T&#xFC;bingen</city>
<country country="DE">Germany</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Johan L. K. Van Hove, Department of Pediatrics, Section of Clinic Genetics and Metabolism, University of Colorado, Education 2 South, L28&#x2010;4114, 13121 East 17th Avenue, Aurora, CO 80045.Email: <email>johan.vanhove@childrenscolorado.org</email><bold>Communicating Editor:</bold> Saskia Brigitte Wortmann<break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>4</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <volume>43</volume>
      <issue>5</issue>
      <issue-id pub-id-type="doi">10.1002/jimd.v43.5</issue-id>
      <fpage>1024</fpage>
      <lpage>1036</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>9</month>
          <year>2019</year>
        </date>
        <date date-type="rev-recd">
          <day>18</day>
          <month>2</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>3</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2020 SSIEM <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2020 The Authors. <italic>Journal of Inherited Metabolic Disease</italic> published by John Wiley &amp; Sons Ltd on behalf of SSIEM</copyright-statement>
        <license license-type="creativeCommonsBy-nc-nd">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x2010;commercial and no modifications or adaptations are made.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:JIMD-43-1024.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>Hydrogen sulfide, a signaling molecule formed mainly from cysteine, is catabolized by sulfide:quinone oxidoreductase (gene <italic>SQOR</italic>). Toxic hydrogen sulfide exposure inhibits complex IV. We describe children of two families with pathogenic variants in <italic>SQOR</italic>. Exome sequencing identified variants; SQOR enzyme activity was measured spectrophotometrically, protein levels evaluated by western blotting, and mitochondrial function was assayed. In family A, following a brief illness, a 4&#x2010;year&#x2010;old girl presented comatose with lactic acidosis and multiorgan failure. After stabilization, she remained comatose, hypotonic, had neurostorming episodes, elevated lactate, and Leigh&#x2010;like lesions on brain imaging. She died shortly after. Her 8&#x2010;year&#x2010;old sister presented with a rapidly fatal episode of coma with lactic acidosis, and lesions in the basal ganglia and left cortex. Muscle and liver tissue had isolated decreased complex IV activity, but normal complex IV protein levels and complex formation. Both patients were homozygous for c.637G&#x2009;&gt;&#x2009;A, which we identified as a founder mutation in the Lehrerleut Hutterite with a carrier frequency of 1 in 13. The resulting p.Glu213Lys change disrupts hydrogen bonding with neighboring residues, resulting in severely reduced SQOR protein and enzyme activity, whereas sulfide generating enzyme levels were unchanged. In family B, a boy had episodes of encephalopathy and basal ganglia lesions. He was homozygous for c.446delT and had severely reduced fibroblast SQOR enzyme activity and protein levels. SQOR dysfunction can result in hydrogen sulfide accumulation, which, consistent with its known toxicity, inhibits complex IV resulting in energy failure. In conclusion, SQOR deficiency represents a new, potentially treatable, cause of Leigh disease.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="jimd12232-kwd-0001">complex IV</kwd>
        <kwd id="jimd12232-kwd-0002">hydrogen sulfide</kwd>
        <kwd id="jimd12232-kwd-0003">Leigh disease</kwd>
        <kwd id="jimd12232-kwd-0004">sulfide:quinone oxidoreductase</kwd>
        <kwd id="jimd12232-kwd-0005">treatment</kwd>
      </kwd-group>
      <funding-group>
        <award-group id="funding-0001">
          <funding-source>Children's Diabetes Foundation</funding-source>
        </award-group>
        <award-group id="funding-0002">
          <funding-source>
            <institution-wrap>
              <institution>Children's Hospital Colorado </institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/100007180</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>William R Hummel Homocystinuria Research Fund</award-id>
        </award-group>
        <award-group id="funding-0003">
          <funding-source>Children's Hospital Colorado Foundation</funding-source>
          <award-id>Ehst&#x2010;Hummel_Kaufmann Family Endowed Chair in Inherited Metabolic Disease</award-id>
        </award-group>
        <award-group id="funding-0004">
          <funding-source>Daniel and Janet Mordecai Foundation</funding-source>
          <award-id>Child Health Research Internship</award-id>
        </award-group>
        <award-group id="funding-0005">
          <funding-source>
            <institution-wrap>
              <institution>Deutsche Forschungsgemeinschaft </institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/501100001659</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>418081722</award-id>
        </award-group>
        <award-group id="funding-0006">
          <funding-source>German Bunderministerium f&#xFC;r Bildung und Forsung</funding-source>
          <award-id>FKZ 01ZX1405C</award-id>
        </award-group>
        <award-group id="funding-0007">
          <funding-source>Miracles for Mito</funding-source>
        </award-group>
        <award-group id="funding-0008">
          <funding-source>
            <institution-wrap>
              <institution>National Center for Advancing Translational Sciences </institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/100006108</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>UL1 TR002535</award-id>
        </award-group>
        <award-group id="funding-0009">
          <funding-source>
            <institution-wrap>
              <institution>National Institute of General Medical Sciences </institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/100000057</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>R35GM130183</award-id>
          <award-id>F32GM122357</award-id>
        </award-group>
        <award-group id="funding-0010">
          <funding-source>
            <institution-wrap>
              <institution>U.S. Department of Health and Human Services (US) </institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/100000016</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>PHH18&#x2010;0157JT</award-id>
        </award-group>
        <award-group id="funding-0011">
          <funding-source>University of Tuebingen</funding-source>
          <award-id>2435&#x2010;0&#x2010;0</award-id>
        </award-group>
        <award-group id="funding-0012">
          <funding-source>William R. Hummel Homocystinuria Research Fund</funding-source>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="1"/>
        <page-count count="13"/>
        <word-count count="8296"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>September 2020</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.2 mode:remove_FC converted:07.10.2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="jimd12232-cit-9001">
<string-name>
<surname>Friederich</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Elias</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Kuster</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Pathogenic variants in <italic>SQOR</italic> encoding sulfide:quinone oxidoreductase are a potentially treatable cause of Leigh disease</article-title>. <source xml:lang="en">J Inherit Metab Dis</source>. <year>2020</year>;<volume>43</volume>:<fpage>1024</fpage>&#x2013;<lpage>1036</lpage>. <pub-id pub-id-type="doi">10.1002/jimd.12232</pub-id>
<pub-id pub-id-type="pmid">32160317</pub-id></mixed-citation>
</p>
      <fn-group id="jimd12232-ntgp-0001">
        <fn id="jimd12232-note-0001">
          <p>
<bold>Communicating Editor:</bold> Saskia Brigitte Wortmann</p>
        </fn>
        <fn id="jimd12232-note-1002">
          <p>
<bold>Funding information</bold> Children's Diabetes Foundation; Children's Hospital Colorado, Grant/Award Number: William R Hummel Homocystinuria Research Fund; Children's Hospital Colorado Foundation, Grant/Award Number: Ehst&#x2010;Hummel_Kaufmann Family Endowed Chair in Inherited Metabolic Disease; Daniel and Janet Mordecai Foundation, Grant/Award Number: Child Health Research Internship; Deutsche Forschungsgemeinschaft, Grant/Award Number: 418081722; German Bunderministerium f&#xFC;r Bildung und Forsung, Grant/Award Number: FKZ 01ZX1405C; Miracles for Mito; National Center for Advancing Translational Sciences, Grant/Award Number: UL1 TR002535; National Institute of General Medical Sciences, Grant/Award Numbers: R35GM130183, F32GM122357; U.S. Department of Health and Human Services (US), Grant/Award Number: PHH18&#x2010;0157JT; University of Tuebingen, Grant/Award Number: 2435&#x2010;0&#x2010;0; William R. Hummel Homocystinuria Research Fund</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body id="jimd12232-body-0001">
    <sec id="jimd12232-sec-0001">
      <label>1</label>
      <title>INTRODUCTION</title>
      <p>Despite the purported role of hydrogen sulfide (H<sub>2</sub>S) as a signaling molecule with multiple physiologic functions, few inherited disorders have been described involving its metabolism or function.<xref rid="jimd12232-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="jimd12232-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> Here, we describe a new disorder of H<sub>2</sub>S metabolism.</p>
      <p>In brain, H<sub>2</sub>S increases cAMP, stimulates NMDA&#x2010;receptor mediated responses including long&#x2010;term potentiation, and stimulates calcium influx in astrocytes. In the vascular system, it promotes vasodilatation and angiogenesis.<xref rid="jimd12232-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="jimd12232-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> It upregulates antioxidant systems, anti&#x2010;inflammatory, and cytoprotective genes.</p>
      <p>The toxicity of excess H<sub>2</sub>S, such as occurs during exposure in industrial accidents, results in part from inhibiting cytochrome c oxidase, including by coordination with the iron of heme a.<xref rid="jimd12232-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> It changes the ventilatory drive possibly by inhibiting carbonic anhydrase, and can cause pulmonary edema and cardiac depression. Chronic H<sub>2</sub>S accumulation has been implicated in ethylmalonic encephalopathy and related to inhibition of short chain acyl&#x2010;CoA dehydrogenase and loss of cytochrome c oxidase.<xref rid="jimd12232-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="jimd12232-bib-0005" ref-type="ref">
<sup>5</sup>
</xref>, <xref rid="jimd12232-bib-0006" ref-type="ref">
<sup>6</sup>
</xref>, <xref rid="jimd12232-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> Finally, H<sub>2</sub>S has been implicated in the pathophysiology of primary coenzyme Q deficiency.<xref rid="jimd12232-bib-0008" ref-type="ref">
<sup>8</sup>
</xref>, <xref rid="jimd12232-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>
</p>
      <p>The metabolism of H<sub>2</sub>S is complex (Figure <xref rid="jimd12232-fig-0001" ref-type="fig">1</xref>). At physiological pH, H<sub>2</sub>S consists of dissolved gaseous H<sub>2</sub>S in equilibrium with HS<sup>&#x2212;</sup>. It is primarily generated from cysteine via the activity of three enzymes. In most tissues, the majority of H<sub>2</sub>S production is derived via &#x3B1;,&#x3B2;&#x2010;elimination by cystathionine &#x3B3;&#x2010;lyase (CTH) upon <sc>l</sc>&#x2010;cysteine to form <sc>l</sc>&#x2010;serine and H<sub>2</sub>S.<xref rid="jimd12232-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>, <xref rid="jimd12232-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> Also, H<sub>2</sub>S is formed in the condensation reaction of cystathionine &#x3B2;&#x2010;synthase (CBS) when <sc>l</sc>&#x2010;serine is substituted by <sc>l</sc>&#x2010;cysteine. Further, <sc>l</sc>&#x2010;cysteine is transaminated by cysteine aminotransferase (CAT) with &#x3B1;&#x2010;ketoglutarate forming 3&#x2010;mercaptopyruvate, which is then acted upon by mercaptopyruvate sulfurtransferase (MPST) to release H<sub>2</sub>S in mitochondria and in the cytosol.<xref rid="jimd12232-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> In the brain, <sc>d</sc>&#x2010;cysteine can be oxidized by <sc>d</sc>&#x2010;amino&#x2010;oxidase to mercaptopyruvate, the substrate for MPST.<xref rid="jimd12232-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> Finally, gut bacteria produce H<sub>2</sub>S, which is rapidly metabolized in the intestinal epithelium.<xref rid="jimd12232-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="jimd12232-bib-0013" ref-type="ref">
<sup>13</sup>
</xref>, <xref rid="jimd12232-bib-0014" ref-type="ref">
<sup>14</sup>
</xref>, <xref rid="jimd12232-bib-0015" ref-type="ref">
<sup>15</sup>
</xref>
</p>
      <fig fig-type="FIGURE" xml:lang="en" id="jimd12232-fig-0001" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>The metabolism of hydrogen sulfide. Hydrogen sulfide (H<sub>2</sub>S) is formed from cysteine by cystathionine &#x3B2;&#x2010;synthase (CBS) or by cystathionine&#x2010;&#x3B3;&#x2010;lyase (CTH), or after transamination via cysteine aminotransferase (CAT) and the action of mercaptopyruvate sulfur transferase (MPST). Cysteine is also produced by gut bacteria. Cysteine is oxidized by cysteine dioxygenase (CDO) in the pathway to taurine synthesis. H<sub>2</sub>S is primarily oxidized by sulfide:quinone oxidoreductase (SQOR) with the electrons transferred to coenzyme Q (CoQ), and with concomitant sulfur transfer to glutathione (GSH) to form glutathione persulfide (GSSH). GSSH is then oxidized to form sulfite by persulfide dioxygenase (SDO, gene <italic>ETHE1</italic>), which is further oxidized to sulfate by sulfite oxidase (SUOX). GSSH can also be converted to thiosulfate by thiosulfate sulfurtransferase (TST). Accumulating hydrogen sulfide can inhibit respiration at the level of complex IV. Other abbreviations used: CoQ is oxidized coenzyme Q, CoQH2 is reduced coenzyme Q, Cytc is cytochrome c, &#x3B1;&#x2010;KG is &#x3B1;&#x2010;ketoglutarate, SO<sub>3</sub>
<sup>2&#x2212;</sup> is sulfite, SO<sub>4</sub>
<sup>2&#x2212;</sup> is sulfate, SSO<sub>3</sub>
<sup>2&#x2212;</sup> is thiosulfate. MPST is variably localized in both the mitochondria and cytosol</p>
        </caption>
        <graphic id="nlm-graphic-1" xlink:href="JIMD-43-1024-g001"/>
      </fig>
      <p>H<sub>2</sub>S is primarily oxidized via sulfide:quinone oxidoreductase, an inner mitochondrial membrane protein encoded by the <italic>SQOR</italic> gene (previously called <italic>SQRDL</italic>) (OMIM# 617658). A cysteine persulfide is transiently formed in the SQOR active site while electrons from H<sub>2</sub>S oxidation reduce coenzyme Q via the cofactor FAD.<xref rid="jimd12232-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> The sulfane sulfur from this persulfide intermediate is then transferred to the physiological acceptor glutathione forming glutathione persulfide (GSSH).<xref rid="jimd12232-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="jimd12232-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> In vitro, sulfite, cyanide, and other acceptors can substitute for glutathione forming thiosulfate, thiocyanate, and other products.<xref rid="jimd12232-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> Glutathione persulfide is oxidized by persulfide dioxygenase (encoded by the gene <italic>ETHE1</italic>, pathogenic variants in this gene are implicated in ethylmalonic encephalopathy) to sulfite, which can be further oxidized to sulfate by sulfite oxidase or metabolized by thiosulfate sulfurtransferase to thiosulfate.<xref rid="jimd12232-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>
</p>
      <p>Leigh disease is a frequent neurologic presentation of genetic defects in mitochondrial bioenergetics.<xref rid="jimd12232-bib-0019" ref-type="ref">
<sup>19</sup>
</xref> It is highly heterogenous genetically with more than 75 causative genes identified, yet the genetic cause for many patients remains unresolved.<xref rid="jimd12232-bib-0020" ref-type="ref">
<sup>20</sup>
</xref> Most patients have defects in structural genes of the respiratory chain complex, or in processes involving transcription, translation, or assembly of the protein complexes including their multiple cofactors. Defects in complex IV are a recurring cause of Leigh disease.<xref rid="jimd12232-bib-0021" ref-type="ref">
<sup>21</sup>
</xref> Very few mitochondrial disorders are related to secondary toxic inhibition of respiratory chain enzyme complexes. Few mitochondrial disorders have an effective treatment option.</p>
      <p>Here, we present children from two families who developed Leigh disease. The genetic defect was identified in the <italic>SQOR</italic> gene, and functional assays show abrogated SQOR enzyme activity and isolated decreased complex IV activity, but normal complex IV protein levels and complex formation. Recognition of this new genetic cause of Leigh disease is clinically important as it identifies a potentially treatable condition.</p>
    </sec>
    <sec id="jimd12232-sec-0002">
      <label>2</label>
      <title>METHODS</title>
      <sec id="jimd12232-sec-0003">
        <label>2.1</label>
        <title>Subjects</title>
        <p>All procedures were done in accordance with the ethical standards of the ethics committee in accordance with the Helsinki Declaration of 1975 and as revised in 2000. Studies at the University of Colorado were done following IRB&#x2010;approved protocols 07&#x2010;0386 and 16&#x2010;0146. Studies at Shodair Children's Hospital in Montana were done according to IRB&#x2010;approved protocol IRB00008287. For studies of identifiable living human subjects, written informed consent was obtained prior to initiation of research as outlined in the IRB&#x2010;approved study. The study was approved by the ethics committee of the University of Tuebingen (437/2018BO1). The clinical histories were reviewed by clinical geneticists, and brain magnetic resonance imaging (MRI) studies were reviewed by a pediatric neuroradiologist (D. M.).</p>
      </sec>
      <sec id="jimd12232-sec-0004">
        <label>2.2</label>
        <title>Exome sequencing</title>
        <p>Exome sequencing was performed on the index cases and their parents. For an initial estimate of the carrier rate in the Hutterite population, de&#x2010;identified DNA samples from this population that had been previously submitted for diagnostic studies for variable indications were screened by high&#x2010;resolution melt curve analysis and Sanger sequencing as described in Supplemental Methods. The carrier incidence in the general population was identified from the gnomAD database using a methodology as described in Supplemental Methods.<xref rid="jimd12232-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>
</p>
      </sec>
      <sec id="jimd12232-sec-0005">
        <label>2.3</label>
        <title>Analysis of respiratory chain enzyme activities and assembly</title>
        <p>Respiratory chain enzyme activities of complexes I, II, II&#x2009;+&#x2009;III, III, IV, and citrate synthase were analyzed in duplicate in post&#x2010;600&#xD7; g supernatants isolated from liver and muscle of subject A.II&#x2010;3 and from fibroblasts of subject B.II&#x2010;3 as described previously.<xref rid="jimd12232-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> Ratios of enzyme activities to either citrate synthase or complex II activities were calculated and expressed as Z&#x2010;scores of the normal distribution established in control samples. Solubilized inner mitochondrial membrane fractions isolated by differential centrifugation from liver and muscle from subject A.II&#x2010;3 and from fibroblasts from subject B.II&#x2010;3 were separated by blue native polyacrylamide gel electrophoresis (BN&#x2010;PAGE) and evaluated by in&#x2010;gel activity staining assays as described previously.<xref rid="jimd12232-bib-0023" ref-type="ref">
<sup>23</sup>
</xref>
</p>
        <p>Complex IV assembly was analyzed in isolated mitochondrial membrane fractions obtained from liver and muscle from subject A.II&#x2010;3 using nondenaturing clear native PAGE followed by western blot analysis using the antibody against COXIV. Complex I assembly was analyzed in mitochondrial membrane fractions using nondenaturing BN&#x2010;PAGE followed by western blot analysis using the antibody against NDUFS2, as described previously.<xref rid="jimd12232-bib-0024" ref-type="ref">
<sup>24</sup>
</xref> In control samples, this assay shows only a holocomplex at 1 MDa and a faint band at 400&#x2009;kDa in muscle samples, or at 230&#x2009;kDa in fibroblasts.</p>
      </sec>
      <sec id="jimd12232-sec-0006">
        <label>2.4</label>
        <title>Western blot analysis of mitochondrial proteins including SQOR</title>
        <p>In subject A.II&#x2010;3, complex IV integrity was evaluated using an antibody against COXIV and complex I integrity was evaluated using and antibody against NDUFB8 on western blot analysis. The amount of SQOR protein was determined by western blot analysis on mitochondrial inner membrane fractions. The levels of H<sub>2</sub>S generating enzymes were evaluated by western blot analysis using antibodies to CBS, CTH, MPST, and cysteine dioxygenase (CDO). All methods are described in Supplemental Methods, and the source and specifications of all antibodies used are listed in Supplemental Table <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S1</xref>.</p>
      </sec>
      <sec id="jimd12232-sec-0007">
        <label>2.5</label>
        <title>Analysis of SQOR enzyme activity in liver, blood cells, and fibroblasts</title>
        <p>The activity of SQOR was measured spectrophotometrically in mitochondrial membrane fractions isolated from liver and in lysates derived from peripheral blood mononuclear cells (PBMCs) and from fibroblasts as previously described for purified protein with the modifications described in detail in Supplemental Methods.<xref rid="jimd12232-bib-0026" ref-type="ref">
<sup>26</sup>
</xref> The reaction uses sulfite as acceptor, following coenzyme Q<sub>1</sub> reduction spectrophotometrically for 5 to 8 minutes at 278&#x2009;nm. The kinetic parameters for human SQOR enzyme were evaluated in human liver and fibroblast samples.</p>
      </sec>
      <sec id="jimd12232-sec-0008">
        <label>2.6</label>
        <title>Protein modeling, purification, and in vitro characterization of the human SQOR mutant</title>
        <p>The <italic>SQOR</italic> variant was mapped on the crystal structure of the human SQOR protein (PDB: 6O1C)<xref rid="jimd12232-bib-0027" ref-type="ref">
<sup>27</sup>
</xref> using PyMol.<xref rid="jimd12232-bib-0028" ref-type="ref">
<sup>28</sup>
</xref> The human SQOR mutant protein p.Glu213Lys was purified as reported previously for the wild type enzyme<xref rid="jimd12232-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> and the absorption spectrum and concentration estimated as described in Supplemental Methods.</p>
      </sec>
    </sec>
    <sec id="jimd12232-sec-0009">
      <label>3</label>
      <title>RESULTS</title>
      <sec id="jimd12232-sec-0010">
        <label>3.1</label>
        <title>Case Reports</title>
        <sec id="jimd12232-sec-0011">
          <label>3.1.1</label>
          <title>Family A</title>
          <p>The proband, subject II&#x2010;3, was a 4&#x2010;year&#x2010;old girl born to consanguineous Lehrerleut Hutterite parents, whose grandparents were first cousins (Figure <xref rid="jimd12232-fig-0002" ref-type="fig">2A</xref>). She had a history of recovering slower from infections than her siblings, but otherwise had no health concerns including no gastrointestinal symptoms. At onset of the illness, during the day she was more tired and vomited, and in the evening became rapidly encephalopathic with an episode of tonic seizures. Upon presentation, she was comatose with seizure&#x2010;like movements, and Kussmaul breathing due to lactic acidosis with pH 6.86, anion gap 31, lactate 17.3&#x2009;mM, and uric acid 7.8 mg/dL. She developed shock, respiratory insufficiency evolving into acute respiratory distress syndrome, and multi&#x2010;organ failure including liver failure with increased prothrombin time INR 1.76 and decreased clotting factors V and VII, mild hypoglycemia 47&#x2009;mg/dL, mild hyperammonemia 112&#x2009;&#x3BC;M, hypoalbuminemia 2.9 g/L, but normal cortisol. With supportive therapy, the multiorgan failure stabilized rapidly over the next days, but coma (Glasgow coma scale [GCS] 5, decorticate posturing) without further seizures, hypoalbuminemia (2.0&#x2010;2.4 g/dL, normal 3.5&#x2010;5.2 g/dL) with otherwise normal liver function (transaminases AST 52&#x2010;88, normal 15&#x2010;50), and lactic acidosis (3&#x2010;5&#x2009;mM with lactate/pyruvate ratio 17 and cerebrospinal fluid [CSF] lactate 3.0&#x2009;mM) persisted. Creatine kinase peaked at 722&#x2009;U/L and remained mildly elevated. In subsequent weeks, she had generalized hypotonia, and episodes of neurostorming with tachycardia, hypertension, and potentially pain, partially responding to treatment with phenobarbital, levetiracetam, baclofen, diazepam, and propranolol. She also developed a thrombus in the right iliac to femoral vein requiring anticoagulation. She died a few days after discharge.</p>
          <fig fig-type="FIGURE" xml:lang="en" id="jimd12232-fig-0002" orientation="portrait" position="float">
            <label>FIGURE 2</label>
            <caption>
              <p>The SQOR pathogenic variant causes lack of protein and enzyme activity. A, In family A, a homozygous pathogenic variant c.637G&#x2009;&gt;&#x2009;A in exon 5 was identified in subjects A.II&#x2010;2 and A.II&#x2010;3 indicated by a filled circle, whereas subjects A.I&#x2010;1, A.I&#x2010;2, A.II&#x2010;1, and A.II&#x2010;4 are carriers for this pathogenic variant. B, In family B, the children are each homozygous for the variant c.446delT whereas the parents are heterozygous carriers. C, Sanger sequencing results of both variants in subjects A.II&#x2010;3 and B.II&#x2010;3 are shown. D, The variant c.637G&#x2009;&gt;&#x2009;A codes for p.(Glu213Lys) which is mapped on the crystal structure of the human SQOR protein (PDB: 6O1C). The human SQOR monomer is shown in gray ribbon with the flavin cofactor (yellow) and select residues (green) are shown in stick display. Glu213 is relatively surface exposed. The close&#x2010;up view shows that the side chain of Glu213 interacts with Arg217 and Arg222. The Glu213Lys mutation is predicted to disrupt electrostatic stabilization of the arginine side chains. E, The SQOR protein (at approx. 50&#x2009;kDa) is virtually absent in the patient liver and strongly reduced in muscle as shown by western blot, using ANT (approx. 33&#x2009;kDa) as a loading control in subject A.II&#x2010;3 and in fibroblast of subject B.II&#x2010;3</p>
            </caption>
            <graphic id="nlm-graphic-3" xlink:href="JIMD-43-1024-g002"/>
          </fig>
          <p>Workup for infectious agents and toxins was negative. The acylcarnitine profile, carnitine levels, 3&#x2010;methylglutaconic acid, thiamin pyrophosphate level, and plasma, urine and CSF amino acids levels were all normal. Urine organic acids showed evidence of lactic acidosis and ketosis. The electroencephalogram showed diffuse slowing and lack of reactivity but no epileptiform activity, and full cardiac evaluation including echocardiogram was normal. Brain MRI on the fourth day of illness showed T2 prolongation and diffusion restriction in the caudate, putamina, and globi pallidi (Figure <xref rid="jimd12232-fig-0003" ref-type="fig">3A,B</xref>, white arrowheads). There was also diffusion restriction in the posterior part of the hippocampi (Figure <xref rid="jimd12232-fig-0003" ref-type="fig">3B</xref> white arrows), medial left temporal lobe, posterior inferior thalamus and the mammillary bodies (Figure <xref rid="jimd12232-fig-0003" ref-type="fig">3C</xref>, white notched arrowheads). Further, there was increased T2 and FLAIR signal in the cerebral peduncles, dentate nuclei, and medial thalami, but brain stem, cerebellum, cortex and white matter were normal. Brain magnetic resonance spectroscopy (MRS) over the right basal ganglia showed a large lactate peak six times larger than the choline peak with a depressed <italic>N</italic>&#x2010;acetylaspartate peak. Biopsies of muscle and liver obtained for mitochondrial evaluation had normal histology and electron microscopy including of the mitochondrial architecture, and skin biopsy electron microscopy was normal without evidence of storage products. Nextgen sequencing of mitochondrial DNA showed normal sequence without evidence for deletions.<xref rid="jimd12232-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> Clinical exome sequencing was reported as negative without pathogenic variants identified in known disease&#x2010;causing genes.</p>
          <fig fig-type="FIGURE" xml:lang="en" id="jimd12232-fig-0003" orientation="portrait" position="float">
            <label>FIGURE 3</label>
            <caption>
              <p>Brain magnetic resonance imaging in patients affected by SQOR deficiency. A&#x2010;C, Axial diffusion&#x2010;weighted brain MR images of patient A.II&#x2010;3 demonstrated symmetric restricted diffusion and edema involving the basal ganglia (white arrowheads), hippocampi (white arrows), and mammillary bodies (white notched arrowheads). D&#x2010;E, Axial diffusion&#x2010;weighted brain MR images of patient A.II&#x2010;2 reveal predominantly left&#x2010;sided restricted diffusion and edema of the cerebral cortices (white arrows) and symmetric restricted diffusion and edema of the basal ganglia (white arrowheads). F, Single voxel proton MR spectroscopy (TE = 144) interrogating the left frontal lobe of patient A.II&#x2010;2 shows a large inverted lactate doublet at 1.3 ppm. G, In patient B.II&#x2010;3 at age 4 4/12&#x2009;years, axial T2&#x2010;weighted brain MR image illustrated patchy increased signal involving the splenium of the corpus callosum (white arrows). H&#x2010;I, One year later for the same patient, axial T2&#x2010;weighted brain MR images show symmetric edema of the basal ganglia (white arrowheads) and anteromedial thalami (white notched arrowheads), all of which had reduced diffusivity (not shown)</p>
            </caption>
            <graphic id="nlm-graphic-5" xlink:href="JIMD-43-1024-g003"/>
          </fig>
          <p>Subject II&#x2010;2, the older sister, was generally healthy, but developed migraines 5 months prior to presentation. At age 8&#x2009;years, she developed a fever, nausea and vomiting, and rapidly became comatose with apnea requiring intubation. She had a large anion gap metabolic acidosis with elevated lactate (peak 22&#x2009;mmol/L) with lactate/pyruvate ratio 51, with otherwise normal blood values. She was tachycardic but otherwise had normal cardiovascular function. She had depressed encephalopathic function on EEG with spike waves over the left frontal area. She died 3&#x2009;days later.</p>
          <p>On brain MRI, she had restricted diffusion of the left frontoparietal cortex (Figure <xref rid="jimd12232-fig-0003" ref-type="fig">3D,E</xref>, white arrows) and right frontal cortex (not labeled). She had restricted diffusion of caudate nuclei and putamina (Figure <xref rid="jimd12232-fig-0003" ref-type="fig">3E</xref>). MRS of the right basal ganglia revealed a large lactate inverted doublet, increased choline and reduced <italic>N</italic>&#x2010;acetylaspartate signal (Figure <xref rid="jimd12232-fig-0003" ref-type="fig">3F</xref>, white notched arrowhead).</p>
        </sec>
        <sec id="jimd12232-sec-0012">
          <label>3.1.2</label>
          <title>Family B</title>
          <p>Subject II&#x2010;3 is a male child born to consanguineous parents of Turkish descent (cousins three times removed), who has two healthy sisters (Figure <xref rid="jimd12232-fig-0002" ref-type="fig">2B</xref>). At age 4 4/12&#x2009;years, following gastroenteritis with diarrhea and 48&#x2009;hours fasting, he presented encephalopathic with decreased consciousness (GCS 12), dyskinesia and mydriasis. On admission, he had mild hypoglycemia 50&#x2009;mg/dL, mild hyperammonemia 100&#x2009;&#x3BC;M, and metabolic acidosis (pH 7.23, bicarbonate 12&#x2009;mmol/L, base excess &#x2212;14&#x2009;mmol/L) with elevated lactate 6.0&#x2009;mmol/L, and large ketones in urine. He had elevated creatine phosphokinase, myoglobin, and transaminases. Urine organic acids showed elevated lactate, ketones, and dicarboxylic acids. Serum acylcarnitine profile was consistent with ketosis, and plasma amino acids showed elevations of glutamine, lysine, proline, alanine, methionine, and tyrosine with low citrulline, whereas CSF amino acids were generally normal (Supplemental Table <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S2</xref>). Brain MRI showed lesions of the splenium of the corpus callosum (Figure <xref rid="jimd12232-fig-0003" ref-type="fig">3G</xref>, white arrows), felt to be clinically and radiographically consistent with mild encephalitis/encephalopathy with reversible splenial lesion (MERS). He improved with supportive therapy with intravenous glucose and vitamins, and respiratory support was not required after 2&#x2009;days. Neurological signs of ptosis, strabismus and ataxia persisted for a few months before recovering, and the MRI lesions resolved after 4&#x2009;months (not shown).</p>
          <p>At age 5 6/12&#x2009;years, following diarrhea, fever and fasting for 24&#x2009;hours, he presented again encephalopathic with decreased consciousness (GCS 10), mild hypoglycemia 56&#x2009;mg/dL, metabolic acidosis (pH 7.3, bicarbonate 14.2&#x2009;mmol/L), elevated serum lactate 6.5&#x2009;mmol/L, and in urine elevated lactate, ketones, and dicarboxylic acids. Plasma ammonia and muscle enzymes remained normal. He recovered again with intravenous glucose administration. He was stable for several years but had learning difficulties and unilateral hearing loss.</p>
          <p>At age 13 6/12&#x2009;years, he had headache, asthenia and anorexia for 36&#x2009;hours, and became stuporous without metabolic abnormalities. Brain MRI demonstrated hyperintense lesions on T2&#x2010;weighted imaging of the caudate nuclei and putamina (Figure <xref rid="jimd12232-fig-0003" ref-type="fig">3H&#x2010;I</xref>, white arrowheads), and the ventromedial aspects of the thalami (Figure <xref rid="jimd12232-fig-0003" ref-type="fig">3I</xref>, white notched arrowheads). Clinically, he recovered completely within 2&#x2009;weeks. He has remained stable and generally healthy, except for easy fatigue and learning difficulties with memory and attention deficits.</p>
          <p>A fasting test performed outside an acute episode showed normal ketogenesis. Fibroblasts showed normal enzyme activities of pyruvate carboxylase and succinyl&#x2010;CoA:3&#x2010;keto acid coenzyme A transferase (SCOT), and leucocytes had normal pyruvate dehydrogenase activity. Molecular analysis of <italic>SLC19A3</italic> and <italic>DLD</italic> was normal. Methemoglobin levels were borderline elevated 2.1% and 2.9% (normal &lt;2%).</p>
        </sec>
      </sec>
      <sec id="jimd12232-sec-0013">
        <label>3.2</label>
        <title>Mitochondrial functional studies</title>
        <p>In subject A.II&#x2010;3, analysis of the respiratory chain enzyme complexes during an acute episode showed markedly reduced complex IV activity with mildly decreased complex II activity, more so in muscle than in liver (Table <xref rid="jimd12232-tbl-0001" ref-type="table">1</xref>). Surprisingly, BN PAGE analysis in muscle and liver showed only a mild decrease in complex IV activity within the range of normal variation (Figure <xref rid="jimd12232-fig-0004" ref-type="fig">4A</xref>), suggesting that it affected enzymatic activity more than the structure or amount of the complex. In fibroblasts, analysis of mitochondrial function was not possible as cells from subject A.II&#x2010;3 rapidly died on initial culture of unknown cause. Fibroblasts from subject B.II&#x2010;3 grew well and both respiratory chain enzyme activities and BN PAGE with in&#x2010;gel activity staining were normal (Supplemental Table <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S3</xref>). We next evaluated directly if the reduced activity evident in muscle and liver of subject A.II&#x2010;3 was due to a decrease in complex IV assembly. Despite the strong decrease in complex IV activity, the amount of a protein COXIV, as a representative of complex IV subunits, was normal (Figure <xref rid="jimd12232-fig-0004" ref-type="fig">4B</xref>). Following separation on a nondenaturing gel, normal amounts of fully assembled complex IV were present in both muscle and liver in the patient compared to three controls (Figure <xref rid="jimd12232-fig-0004" ref-type="fig">4C</xref>). The integrity of complex I assessed by the amount of NDUFB8 as a marker subunit protein was normal, as was its assembly assessed on a nondenaturing gel (Figure <xref rid="jimd12232-fig-0004" ref-type="fig">4D</xref>). Thus, the marked decrease in complex IV activity was not caused by a problem in complex IV biogenesis but rather its function.</p>
        <table-wrap id="jimd12232-tbl-0001" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
          <label>TABLE 1</label>
          <caption>
            <p>Respiratory chain enzyme activities in patient A.II.3</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col align="left" span="1"/>
            <col align="char" char=" (" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char=" (" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char=" (" span="1"/>
            <col align="char" char="." span="1"/>
            <thead valign="bottom">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                <th align="left" valign="bottom" rowspan="1" colspan="1">Activity (controls) nmol&#x2009;min<sup>&#x2212;1</sup> mg protein<sup>&#x2212;1</sup>
</th>
                <th align="left" valign="bottom" rowspan="1" colspan="1">% of normal</th>
                <th align="left" valign="bottom" rowspan="1" colspan="1">SD</th>
                <th align="left" valign="bottom" rowspan="1" colspan="1">Activity/CS</th>
                <th align="left" valign="bottom" rowspan="1" colspan="1">SD</th>
                <th align="left" valign="bottom" rowspan="1" colspan="1">Activity/CO II</th>
                <th align="left" valign="bottom" rowspan="1" colspan="1">SD</th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td colspan="8" align="left" valign="top" rowspan="1">Muscle</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex I</td>
                <td align="char" valign="top" rowspan="1" colspan="1">44.2 (23.6&#x2010;74.8)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">98%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.1</td>
                <td align="char" valign="top" rowspan="1" colspan="1">176 (98&#x2010;271)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.1</td>
                <td align="char" valign="top" rowspan="1" colspan="1">888 (285&#x2010;767)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">1.9</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex II</td>
                <td align="char" valign="top" rowspan="1" colspan="1">49.8 (49.0&#x2010;133.4)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">56%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">&#x2212;1.8</td>
                <td align="char" valign="top" rowspan="1" colspan="1">198 (251&#x2010;573)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">&#x2212;1.8</td>
                <td align="char" valign="top" rowspan="1" colspan="1">NA</td>
                <td align="char" valign="top" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex III</td>
                <td align="char" valign="top" rowspan="1" colspan="1">20.3 (5.7&#x2010;31.4)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">117%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.5</td>
                <td align="char" valign="top" rowspan="1" colspan="1">81 (19&#x2010;72)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.5</td>
                <td align="char" valign="top" rowspan="1" colspan="1">408 (45&#x2010;369)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">1.2</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex II&#x2010;III</td>
                <td align="char" valign="top" rowspan="1" colspan="1">45.7 (34.2&#x2010;107.6)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">72%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">&#x2212;0.7</td>
                <td align="char" valign="top" rowspan="1" colspan="1">182 (172&#x2010;472)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">&#x2212;0.1</td>
                <td align="char" valign="top" rowspan="1" colspan="1">918 (549&#x2010;1226)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.7</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex IV</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.4</bold> (1.1&#x2010;3.8)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>15%</bold>
</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>&#x2212;4.3</bold>
</td>
                <td align="char" valign="top" rowspan="1" colspan="1">2 (4&#x2013;23)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>&#x2212;4.3</bold>
</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>8</bold> (11&#x2010;68)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>&#x2212;4.6</bold>
</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CS</td>
                <td align="char" valign="top" rowspan="1" colspan="1">251.7 (159.8&#x2010;353.3)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">98%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.0</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr>
                <td colspan="8" align="left" valign="top" rowspan="1">Liver</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex I</td>
                <td align="char" valign="top" rowspan="1" colspan="1">60.8 (14.4&#x2010;56.0)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">172%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">1.5</td>
                <td align="char" valign="top" rowspan="1" colspan="1">600 (162&#x2010;730)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.9</td>
                <td align="char" valign="top" rowspan="1" colspan="1">264 (68&#x2010;252)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">1.3</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex II</td>
                <td align="char" valign="top" rowspan="1" colspan="1">230.1 (174.7&#x2010;309.8)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">99%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.1</td>
                <td align="char" valign="top" rowspan="1" colspan="1">2269 (2304&#x2010;3311)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">&#x2212;1.3</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex III</td>
                <td align="char" valign="top" rowspan="1" colspan="1">27.6 (13.8&#x2010;27.6)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">145%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">3.1</td>
                <td align="char" valign="top" rowspan="1" colspan="1">273 (128&#x2010;315)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.6</td>
                <td align="char" valign="top" rowspan="1" colspan="1">120 (50&#x2010;118)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">1.0</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex II&#x2010;III</td>
                <td align="char" valign="top" rowspan="1" colspan="1">50.0 (10.8&#x2010;107.3)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">85%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.4</td>
                <td align="char" valign="top" rowspan="1" colspan="1">493 (138&#x2010;1062)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">&#x2212;0.2</td>
                <td align="char" valign="top" rowspan="1" colspan="1">217 (62&#x2010;383)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.0</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex IV</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.4</bold> (0.5&#x2010;3.2)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>22%</bold>
</td>
                <td align="char" valign="top" rowspan="1" colspan="1">&#x2212;1.8</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>4</bold> (6&#x2010;35)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>&#x2212;2.4</bold>
</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>2</bold> (3&#x2010;13)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">
<bold>&#x2212;2.5</bold>
</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CS</td>
                <td align="char" valign="top" rowspan="1" colspan="1">101.4 (59.5&#x2010;109.3)</td>
                <td align="char" valign="top" rowspan="1" colspan="1">120%</td>
                <td align="char" valign="top" rowspan="1" colspan="1">0.1</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot id="jimd12232-ntgp-0002">
            <fn id="jimd12232-note-0002">
              <p>
<italic>Note</italic>: The activities in muscle and liver tissue of each respiratory chain complex and of the combined complex II&#x2010;III are shown expressed as nmol&#x2009;min<sup>&#x2212;1</sup> mg protein<sup>&#x2212;1</sup> and as a ratio of the activity over citrate synthase activity (activity/CS) and as a ratio over the activity of complex II (activity/Co II). The patient's values are followed by normal values in parentheses and the percentage of the average normal value is provided. The values are also expressed as standard deviations (Z&#x2010;score) of the log transformed values of controls, which are normally distributed. Activities that are reduced are highlighted in bold.</p>
            </fn>
            <fn id="jimd12232-note-0003">
              <p>Abbreviations: CS, citrate synthase; CO II, complex II.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <fig fig-type="FIGURE" xml:lang="en" id="jimd12232-fig-0004" orientation="portrait" position="float">
          <label>FIGURE 4</label>
          <caption>
            <p>Assembly and activity of mitochondrial complexes. A, Mitochondrial complexes were separated on a blue native (BN) gel and assayed with in&#x2010;gel activity staining in muscle (upper panel) and in liver (lower panel). A mild decrease in complex IV staining was observed in muscle for patient A.II&#x2010;3. B, In muscle and liver of patient A.II&#x2010;3 a normal amount of the complex IV subunit COXIV is seen, using citrate synthase as a loading control. C, Both muscle and liver exhibit normal levels of fully assembled complex IV in patient A.II&#x2010;3 compared to control samples as revealed by blue gel followed by western blotting and detection with COXIV antibody. D, The assembly of complex I is normal in patient A.II&#x2010;3 compared to controls as identified by BN gel followed by western blotting and detection with an antibody against NDUFS2</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="JIMD-43-1024-g004"/>
        </fig>
      </sec>
      <sec id="jimd12232-sec-0014">
        <label>3.3</label>
        <title>Genetic studies</title>
        <p>The <italic>SQOR</italic> gene has 8 transcripts. The main protein coding transcript <italic>SQOR</italic>&#x2010;201 has 10 exons. The transcript has 1701&#x2009;bp and encodes a protein of 450 residues (Uniprot Q9Y6N5). Whole exome studies in the proband A.II&#x2010;3 showed a homozygous missense variant NM_021199.4:c.637G&#x2009;&gt;&#x2009;A, p.(Glu213Lys) in exon 5 of the <italic>SQOR</italic> gene, genomic coordinates: hg19:chr15:45965982G&#x2009;&gt;&#x2009;A, which was confirmed by Sanger sequencing (Figure <xref rid="jimd12232-fig-0002" ref-type="fig">2C</xref>). Her sister A.II&#x2010;2 was also homozygous for this variant and both parents and two unaffected siblings were heterozygous carriers (Figure <xref rid="jimd12232-fig-0002" ref-type="fig">2A</xref>). Mutation Taster predicted this variant to be disease&#x2010;causing, Polyphen2 rated it as &#x201C;possibly damaging&#x201D; (score 0.915), and the scaled CADD score was 34 (raw score 5.03). The <italic>SQOR</italic> p.Glu213Lys variant is not reported in 1000 genomes or ExAC. In gnomAD it was present in only one non&#x2010;Finnish European allele (minor allele frequency [MAF] in this population 0.9&#x2009;&#xD7;&#x2009;10<sup>&#x2212;5</sup>, MAF 0.4&#x2009;&#xD7;&#x2009;10<sup>&#x2212;5</sup> in all populations). Phylogenetically, in most species, this amino acid is an acidic residue, either a glutamic acid or an aspartic acid; the mutation changes Glu213 to a basic lysine.</p>
        <p>Whole exome sequencing in subject B.II&#x2010;3 revealed a homozygous 1 bp deletion c.446delT, p.(Leu149Argfs*18), genomic coordinates chr15:45962165delT, in exon 3 of the <italic>SQOR</italic> gene, which was confirmed by Sanger sequencing (Figure <xref rid="jimd12232-fig-0002" ref-type="fig">2C</xref>). This change predicts a loss of SQOR protein function possibly by nonsense&#x2010;mediated decay of the mutant RNA or by introducing a frameshift leading to a premature truncation of protein translation. This variant was present in heterozygous state in gnomAD only once (MAF in this population 3.98&#x2009;&#xD7;&#x2009;10<sup>&#x2212;6</sup>). Sanger sequencing revealed this change also in a homozygous state in the asymptomatic sisters B.II&#x2010;1 and B.II&#x2010;2 (Figure <xref rid="jimd12232-fig-0002" ref-type="fig">2B</xref>).</p>
      </sec>
      <sec id="jimd12232-sec-0015">
        <label>3.4</label>
        <title>SQOR functional studies</title>
        <p>To understand the impact of the mutation on the protein, the missense variant was mapped on the crystal structure of human SQOR (Figure <xref rid="jimd12232-fig-0002" ref-type="fig">2D</xref>). In the structure, Glu&#x2010;213 is remote from the active site, but resides in an &#x3B1;&#x2010;helix and is proximal to Arg&#x2010;217 on the same helix and Arg&#x2010;222 on an adjacent &#x3B1;&#x2010;helix. The side chain of Glu213 is predicted to be involved in hydrogen bonding interactions with the side chains of these two arginine residues (Figure <xref rid="jimd12232-fig-0002" ref-type="fig">2D</xref>). Introduction of the positively charged lysine in the Glu213Lys mutant is predicted to disrupt these electrostatic interactions and destabilize the tertiary structure of the protein. This structure suggests that the Glu213Lys variant is likely to impair protein stability rather than affect the catalytic mechanism.</p>
        <p>Indeed, attempts to express the recombinant Glu213Lys human SQOR protein in <italic>E. coli</italic> using the methods employed for wild type proteins<xref rid="jimd12232-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> as well as several modifications to growth and purification conditions, repeatedly resulted in the majority of the recombinant protein aggregating in inclusion bodies. The yield of soluble Glu213Lys SQOR protein was very low and the protein appeared to be devoid of FAD as assessed by the lack of an associated ultraviolet&#x2010;visible absorption spectrum.</p>
        <p>Western blot analysis showed very low levels of SQOR protein in muscle and liver tissues of subject A.II&#x2010;3 and in fibroblasts of subject B.II&#x2010;3 each compared to three controls (Figure <xref rid="jimd12232-fig-0002" ref-type="fig">2E</xref>).</p>
        <p>To evaluate the functional impact, an SQOR enzyme activity assay using sulfite as acceptor was developed using liver tissue mitochondrial membrane fractions. The initial rate was linearly dependent on lysate protein concentration over the range of 0.064 to 0.698&#x2009;mg protein/mL (final concentration) (<italic>r</italic>
<sup>2</sup> =&#x2009;.98) (Supplemental Figure <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S1</xref>A). A <italic>K</italic>
<sub>M</sub> of 2.2 &#xB1;&#x2009;1.1&#x2009;mM for sulfide and a <italic>V</italic>
<sub>max</sub> of 27.8 &#xB1; 8.9 nmol&#x2009;min<sup>&#x2212;1</sup> mg protein<sup>&#x2212;1</sup> at 37&#xB0;C were observed (Supplemental Figure <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S1</xref>C). The <italic>V</italic>
<sub>max</sub> value was obtained at sulfite concentrations of around 1 to 2&#x2009;mM (Supplemental Figure <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S1</xref>D), and at coenzyme Q<sub>1</sub> concentrations of 100&#x2009;&#x3BC;M (Supplemental Figure <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S1</xref>E). The coefficient of variation (COV) in the same liver tissue sample was 14%. SQOR activity in subject A.II&#x2010;3 liver was severely reduced to 6% of the average of control values (0.71&#x2009;&#xB1;&#x2009;0.57 vs 11.42&#x2009;&#xB1;&#x2009;3.75&#x2009;nmol&#x2009;min<sup>&#x2212;1</sup> mg protein<sup>&#x2212;1</sup>, normal range 7.56&#x2010;16.94; <italic>n</italic> =&#x2009;5) (Supplementary Figure <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S2</xref>A).</p>
        <p>To facilitate future diagnosis of SQOR deficiency, the enzyme assay was modified for use with fibroblasts and PBMCs. In fibroblasts, the initial rate of enzyme activity was linear over a lysate protein concentration range from 0.01 to 0.34&#x2009;mg protein&#x2009;mL<sup>&#x2212;1</sup> (<italic>r</italic>
<sup>2</sup> =&#x2009;.98) (Supplemental Figure <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S1</xref>B). With control fibroblasts, a specific activity of 82.1&#x2009;&#xB1;&#x2009;21.2 nmol&#x2009;min<sup>&#x2212;1</sup> mg protein<sup>&#x2212;1</sup> (normal range 51.6&#x2010;115.2; <italic>n</italic> =&#x2009;12), COV 26% was obtained, whereas subject B.II&#x2010;3 fibroblasts had SQOR activity of 0.41&#x2009;&#xB1;&#x2009;0.16 nmol&#x2009;min<sup>&#x2212;1</sup> mg protein<sup>&#x2212;1</sup>, 0.49% of average control value (Supplemental Figure <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S2</xref>B). Analysis of control PBMCs yielded a specific activity of 43.6 &#xB1;&#x2009;2.1 nmol&#x2009;min<sup>&#x2212;1</sup> mg protein<sup>&#x2212;1</sup> (<italic>n</italic> =&#x2009;8), COV 5%. Additional family members who were found to be carriers for this mutation had 62%, 66%, and 42% of mean control enzyme activity in PBMCs.</p>
        <p>The homozygosity of the patient and the identification of additional carriers in distant family members suggested that Glu213Lys may represent a founder mutation. Targeted mutation screening of de&#x2010;identified DNA samples of 40 subjects from this population identified three carriers (carrier frequency <italic>P</italic> =&#x2009;.08&#x2009;&#xB1;&#x2009;.04), implying an affected incidence of 1 in 711. Untargeted population analysis of the gnomAD database using predictive software estimated a carrier frequency of <italic>P</italic> =&#x2009;.0023 (1 in 215), implying an incidence of 1 in 184&#x2009;477 for biallelic pathogenic variants.</p>
      </sec>
    </sec>
    <sec id="jimd12232-sec-0016">
      <label>4</label>
      <title>DISCUSSION</title>
      <p>The Glu213Lys variant replaces an acidic with a basic amino acid disrupting hydrogen bonding interactions and destabilizing the SQOR protein. This protein instability resulted in strongly reduced protein levels and severely decreased enzyme activity, but not its complete absence. The protein instability severely limited bacterial expression of the recombinant Glu213Lys human SQOR enzyme. These functional data confirm bioinformatic predictions that this variant is pathogenic. It tracks with deficient enzyme activity in the family and represents a founder variant in the Lehrerleut Hutterite population with a carrier frequency estimated to be as high as 1 in 13 based on limited screening of samples from this population. The frameshift mutation in Family B likewise resulted in severely reduced SQOR protein and enzyme activity. These pathogenic variants limited the ability of the patient to metabolize H<sub>2</sub>S, and presumably resulted in episodic accumulation.</p>
      <p>In all patients, acute symptoms were triggered by infections and fasting, episodes associated with protein catabolism. Outside acute events, our patients generally appeared healthy, and likewise two siblings in Family B have remained asymptomatic for prolonged time. They did not exhibit symptoms such as chronic gastrointestinal upset or a tendency for petechiae that have previously been attributed to excess H<sub>2</sub>S in patients with pathogenic variants in <italic>ETHE1</italic> resulting in deficient persulfide dioxygenase activity, the next step in the pathway.<xref rid="jimd12232-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> In contrast to <italic>ETHE1</italic> deficiency, ethylmalonic acid was not noted in urine organic acid analysis, supporting that the inhibition of short chain acyl&#x2010;CoA dehydrogenase could be due to accumulating coenzyme A&#x2010;persulfide in the intact SQOR protein in <italic>ETFE1</italic> deficiency, but not in <italic>SQOR</italic> deficiency.<xref rid="jimd12232-bib-0027" ref-type="ref">
<sup>27</sup>
</xref> Chronic loss of complex IV protein attributed to excess H<sub>2</sub>S in the mouse model of <italic>ETHE1</italic> was also not observed in our patient.<xref rid="jimd12232-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> Rather, a functional deficiency of complex IV activity was seen, while the levels and assembly of complex IV appeared comparable to controls. Deficient complex IV activity results in an acute energy defect which in brain usually presents as Leigh disease,<xref rid="jimd12232-bib-0021" ref-type="ref">
<sup>21</sup>
</xref> although some genetic causes also include myopathy or cardiomyopathy (eg, <italic>SCO2</italic>).<xref rid="jimd12232-bib-0030" ref-type="ref">
<sup>30</sup>
</xref> In our patients, the cardiovascular system appeared to be relatively spared with cardiovascular symptoms limited to transient hypotension and shock present only in the context of multiorgan failure, which recovered with supportive care. Acute H<sub>2</sub>S toxicity causes depression in cardiac contractility and pulseless electrical activity.<xref rid="jimd12232-bib-0031" ref-type="ref">
<sup>31</sup>
</xref> In an animal model of acute H<sub>2</sub>S intoxication leading to 75% mortality, 25% of surviving animals had neurological lesions of neuronal necrosis of the cortex, putamen and thalamus, which closely resembles the symptoms noted in patient A.II&#x2010;2.<xref rid="jimd12232-bib-0031" ref-type="ref">
<sup>31</sup>
</xref> The striking involvement of the hippocampus and mammillary body in patient A.II&#x2010;3 without prolonged seizures likely represents the SQOR deficiency rather than an injury secondary to her poor state. In mouse, SQOR protein is present in the hippocampus (Maclean, unpublished observation<xref rid="jimd12232-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>). Given the long asymptomatic period in subject A.II&#x2010;2 and subjects B.II&#x2010;1 and B.II&#x2010;2, we consider it possible that undiagnosed patients exist, including in the Hutterite population.</p>
      <p>The presence of normal amounts of cytochrome c oxidase complex but severely reduced activity indicates that the fundamental pathophysiological mechanism of SQOR deficiency appears to be due to the resulting accumulation of toxic metabolites, rather than disruption of complex IV biogenesis. Acute illness is associated with catabolism and associated endogenous protein breakdown. The resulting increase in cysteine can increase H<sub>2</sub>S generation, which would accumulate in the absence of sufficient SQOR enzyme activity. At high levels, H<sub>2</sub>S can coordinate to the iron in the heme a group of complex IV resulting in strong inhibition.<xref rid="jimd12232-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> The complete absence of SQOR in yeast impaired growth under obligate aerobic conditions, whereas mutants that retain low levels of activity restored oxidative growth, consistent with the detoxifying role attributed to SQOR.<xref rid="jimd12232-bib-0032" ref-type="ref">
<sup>32</sup>
</xref> We hypothesize that in our patients, the low residual SQOR activity was likely sufficient to support H<sub>2</sub>S clearance during stable episodes but was insufficient during acute illness with catabolism resulting in H<sub>2</sub>S accumulation and toxicity.</p>
      <p>During acute H<sub>2</sub>S intoxication, two pools accumulate: a soluble and diffusible pool of H<sub>2</sub>S gas in equilibrium with the sulfide (HS<sup>&#x2212;</sup>) anion, and a pool of sulfide bound to metalloproteins (eg, hemes) and cysteine residues in a variety of proteins.<xref rid="jimd12232-bib-0031" ref-type="ref">
<sup>31</sup>
</xref>, <xref rid="jimd12232-bib-0033" ref-type="ref">
<sup>33</sup>
</xref> It is unclear to what extent these cysteine adducts can form nonenzymatically in the absence of functional SQOR. The toxicity mechanism in our patients might be partially different from that of acute exogenous H<sub>2</sub>S intoxication. In our patient A.II&#x2010;3, the more severe reduction in complex IV activity was noted in muscle tissue, where the sulfide generating enzymes could not be detected, compared to liver tissue where the enzymes were present and unchanged vs controls (Supplemental Figure <xref rid="jimd12232-supitem-0001" ref-type="supplementary-material">S2</xref>). This illustrates the importance of great diffusibility of H<sub>2</sub>S, which is more soluble and diffusible than oxygen or carbon dioxide.<xref rid="jimd12232-bib-0031" ref-type="ref">
<sup>31</sup>
</xref> A large pool of H<sub>2</sub>S bound to ferrous myoglobin has been proposed to explain the sensitivity of muscle tissue to H<sub>2</sub>S toxicity.<xref rid="jimd12232-bib-0034" ref-type="ref">
<sup>34</sup>
</xref> SQOR has a wide tissue distribution including in neurons, oligodendrocytes and vascular endothelial cells in brain, likely reflecting a need to protect against this toxin that readily diffuses across membranes.<xref rid="jimd12232-bib-0035" ref-type="ref">
<sup>35</sup>
</xref>, <xref rid="jimd12232-bib-0036" ref-type="ref">
<sup>36</sup>
</xref> Rapid diffusion of H<sub>2</sub>S from tissue culture medium can explain the normal complex IV activity in cultured fibroblasts.</p>
      <p>Recognition of the enzymatic basis and intoxication of the respiratory chain in the pathophysiology of SQOR deficiency opens up possible therapeutic opportunities. First, reduction in H<sub>2</sub>S production should be pursued. Since the majority of H<sub>2</sub>S is generated from cysteine catabolism in the body and gut microbiome,<xref rid="jimd12232-bib-0013" ref-type="ref">
<sup>13</sup>
</xref> limiting dietary cysteine and aggressive prevention of episodes triggering catabolism by adequate provision of calories and avoidance of prolonged fasting can be considered. Catabolic episodes likely triggered the acute crisis in our patients. H<sub>2</sub>S is produced by &#x3B3;&#x2010;proteobacteria including certain gram&#x2010;negative and <italic>Clostridia</italic> species, which can be increased by omeprazole or lansoprazole,<xref rid="jimd12232-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> and can be therapeutically reduced by treatment with metronidazole, similar to the treatment of ETHE1 disorder.<xref rid="jimd12232-bib-0037" ref-type="ref">
<sup>37</sup>
</xref> Certain vegetables, such as garlic, onions, and certain cruciferous vegetables contain organic polysulfides, which can directly release H<sub>2</sub>S and could be avoided.<xref rid="jimd12232-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> Next, the toxic effects of accumulated H<sub>2</sub>S could be mitigated. Toxicological studies have shown that hydroxocobalamin can bind H<sub>2</sub>S and pharmacological doses have been used for detoxification during acute H<sub>2</sub>S poisoning, similar to the treatment of cyanide which shares a similar pathophysiology.<xref rid="jimd12232-bib-0031" ref-type="ref">
<sup>31</sup>
</xref>, <xref rid="jimd12232-bib-0033" ref-type="ref">
<sup>33</sup>
</xref>, <xref rid="jimd12232-bib-0038" ref-type="ref">
<sup>38</sup>
</xref> During acute symptomatic periods in illness, acute administration of very high doses of hydroxocobalamin (70&#x2009;mg/kg) may be required. Given the rapidity of onset of life&#x2010;threatening events, which in our patients occurred within hours, preventive daily subcutaneous administration of pharmacologic doses of hydroxocobalamin, as is used to treat cobalamin C disorder, should be considered. Further, methylene blue has been shown to reduce mortality due to acute H<sub>2</sub>S poisoning by reducing its mitochondrial toxicity.<xref rid="jimd12232-bib-0031" ref-type="ref">
<sup>31</sup>
</xref>, <xref rid="jimd12232-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>
</p>
      <p>In summary, we describe a new genetic cause of Leigh disease associated with pathogenic variants in <italic>SQOR</italic>, whereby intermittent accumulation of H<sub>2</sub>S results in acute isolated complex IV deficiency. We developed an enzyme assay that allows noninvasive measurement of the enzyme activity, which is useful for diagnosis. Recognition of SQOR deficiency as a cause of Leigh diseases is clinically important since it suggests several treatment modalities to prevent neurological complications.</p>
    </sec>
    <sec sec-type="COI-statement" id="jimd12232-sec-0018">
      <title>CONFLICT OF INTERESTS</title>
      <p>J. V. H. and A. A. L. participate in clinical trials of mitochondrial disorders by Stealth Biotherapeutics, Inc. All other authors deny any real or apparent conflict of interest in the field of mitochondrial diseases.</p>
    </sec>
    <sec id="jimd12232-sec-0019">
      <title>AUTHOR CONTRIBUTIONS</title>
      <p>Study concept and design: Johan L. K. Van Hove and Marisa W. Friederich. Patient care data: Johan L. K. Van Hove, Abdallah F. Elias, Alice Kuster, Austin A. Larson, Jaclyn Haven, David M. Mirsky, Louise Goujon, Thomas Lefrancois. Molecular data: Marisa W. Friederich, Abdallah F. Elias, Lucia Laugwitz, David Dimmock, Katie Styren, Jonathan Schoof, Maike Friederich, Curtis R. Coughlin, Tobias B. Haack, Johan L. K. Van Hove. Laboratory studies: Marisa W. Friederich, Aaron P. Landry, Logan Ellwood&#x2010;Digel, Hua Jiang, Kenneth N. MacLean, Ruma Banerjee. First draft writing: Marisa W. Friederich, Johan L. K. Van Hove. Critical rewriting: Marisa W. Friederich, Abdallah F. Elias, David M. Mirsky, David Dimmock, Kenneth N. MacLean, Curtis R. Coughlin, Ruma Banerjee, Tobias B. Haack, Johan L. K. Van Hove. Leadership and funding: Marisa W. Friederich, Abdallah F. Elias, Kenneth N. MacLean, Ruma Banerjee, Tobias B. Haack, Johan L. K. Van Hove. Final responsibility and guarantor: Johan L. K. Van Hove.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data" id="jimd12232-supitem-0001">
        <caption>
          <p>
<bold>Appendix</bold>
<bold>S1</bold>: Supporting Information</p>
        </caption>
        <media xlink:href="JIMD-43-1024-s001.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="jimd12232-sec-0017">
      <title>ACKNOWLEDGMENTS</title>
      <p>The authors acknowledge financial support from Children's Hospital Colorado Foundation, Summits for Samantha and Miracles for Mito (J. V. H., M. W. F., A. A. L.). The study was also supported by the NIH grants R35GM130183 to R. B., and F32GM122357 to A. P. L., and by NIH/NCATS Colorado CTSA Grant Number UL1 TR002535. Contents are the authors' sole responsibility and do not necessarily represent official NIH views. L. E. D. was the recipient of a Child Health Research Internship at the CU Anschutz campus, which is supported by the Daniel and Janet Mordecai Foundation, Department of Pediatrics and the Research Institute, Children's Hospital Colorado. K. N. M. gratefully acknowledges financial support from the William R. Hummel Homocystinuria Research Fund and holds the Ehst&#x2010;Hummel&#x2010;Kaufmann Family Endowed Chair in Inherited Metabolic Disease. Sequencing performed at the University of Colorado was performed by the Molecular Biology Unit of the Barbara Davis Center for BioResources Core Facility, which receives support from the Children's Diabetes Foundation, the Davis trust, and the UC&#x2010;AMC Strategic Infrastructure for Research Committee. T. B. H. was supported by the German Bundesministerium f&#xFC;r Bildung und Forschung (BMBF) through the Juniorverbund in der Systemmedizin &#x201C;mitOmics&#x201D; (FKZ 01ZX1405C to T. B. H.), the intramural fort&#xFC;ne program (#2435&#x2010;0&#x2010;0) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) &#x2013; Projektnummer (418081722). The Montana Genetics Program at Shodair Children's Hospital is supported by the Montana Department of Public Health and Human Services (PHH18&#x2010;0157JT MT Clinical Genetics Program). Funding sources had no role in the design or execution of the study, the interpretation of data, or the writing of the study.</p>
    </ack>
    <ref-list id="jimd12232-bibl-0001" content-type="cited-references">
      <title>REFERENCES</title>
      <ref id="jimd12232-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0001">
<string-name>
<surname>Kolluru</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Bir</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Kevil</surname>
<given-names>CG</given-names>
</string-name>. <article-title>Hydrogen sulfide chemical biology: pathophysiological roles and detection</article-title>. <source xml:lang="en">Nitric Oxide</source>. <year>2013</year>;<volume>35</volume>:<fpage>5</fpage>&#x2010;<lpage>20</lpage>.<pub-id pub-id-type="pmid">23850632</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0002">
<string-name>
<surname>Kabil</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Vitvitsky</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>R</given-names>
</string-name>. <article-title>Sulfur as a signaling nutrient through hydrogen sulfide</article-title>. <source xml:lang="en">Annu Rev Nutr</source>. <year>2014</year>;<volume>34</volume>:<fpage>171</fpage>&#x2010;<lpage>205</lpage>.<pub-id pub-id-type="pmid">25033061</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0003">
<string-name>
<surname>Cooper</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>GC</given-names>
</string-name>. <article-title>The inhibition of mitochondrial cytochrome oxidase by the gases carbon monoxide, nitric oxide, hydrogen cyanide and hydrogen sulfide: chemical mechanism and physiological significance</article-title>. <source xml:lang="en">J Bioenerg Biomembr</source>. <year>2008</year>;<volume>40</volume>:<fpage>533</fpage>&#x2010;<lpage>539</lpage>.<pub-id pub-id-type="pmid">18839291</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0004">
<string-name>
<surname>Tiranti</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Viscomi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hildebrandt</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy</article-title>. <source xml:lang="en">Nat Med</source>. <year>2009</year>;<volume>15</volume>:<fpage>200</fpage>&#x2010;<lpage>205</lpage>.<pub-id pub-id-type="pmid">19136963</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0005">
<string-name>
<surname>Di Meo</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Fagiolari</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Prelle</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Viscomi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zeviani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tiranti</surname>
<given-names>V</given-names>
</string-name>. <article-title>Chronic exposure to sulfide causes accelerated degradation of cytochrome c oxidase in ethylmalonic encephalopathy</article-title>. <source xml:lang="en">Antiox Redox Sign</source>. <year>2011</year>;<volume>15</volume>:<fpage>353</fpage>&#x2010;<lpage>362</lpage>.</mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0006">
<string-name>
<surname>Hildebrandt</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Di Meo</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Zeviani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Viscomi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Braun</surname>
<given-names>H&#x2010;P</given-names>
</string-name>. <article-title>Proteome adaptations in Ethe1&#x2010;deficient mice indicate a role in lipid catabolism and cytoskeleton organization via post&#x2010;translational modification</article-title>. <source xml:lang="en">Biosci Rep</source>. <year>2013</year>;<volume>33</volume>:<fpage>575</fpage>&#x2010;<lpage>584</lpage>.</mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0007">
<string-name>
<surname>Di Meo</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Lamperti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tiranti</surname>
<given-names>V</given-names>
</string-name>. <article-title>Mitochondrial diseases caused by toxic compound accumulation: from etiopathology to therapeutic approaches</article-title>. <source xml:lang="en">EMBO Mol Med</source>. <year>2015</year>;<volume>7</volume>:<fpage>1257</fpage>&#x2010;<lpage>1266</lpage>.<pub-id pub-id-type="pmid">26194912</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0008">
<string-name>
<surname>Luna&#x2010;S&#xE1;nchez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hidalgo&#x2010;Guti&#xE9;rrez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hildebrandt</surname>
<given-names>TM</given-names>
</string-name>, et al. <article-title>CoQ deficiency causes disruption of mitochondrial sulfide oxidation, a new pathomechanism associated with this syndrome</article-title>. <source xml:lang="en">EMBO Mol Med</source>. <year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>78</fpage>&#x2010;<lpage>95</lpage>.<pub-id pub-id-type="pmid">27856619</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0009">
<string-name>
<surname>Ziosi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Di Meo</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kleiner</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Coenzyme Q deficiency causes impairment of the sulfide oxidation pathway</article-title>. <source xml:lang="en">EMBO J</source>. <year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>96</fpage>&#x2010;<lpage>111</lpage>.</mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0010">
<string-name>
<surname>Chiku</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Padovani</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Vitvitsky</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>R</given-names>
</string-name>. <article-title>H<sub>2</sub>S biogenesis by human cystathionine &#x3B3;&#x2010;lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2009</year>;<volume>284</volume>:<fpage>11601</fpage>&#x2010;<lpage>11612</lpage>.<pub-id pub-id-type="pmid">19261609</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0011">
<string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Padovani</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Leslie</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Chiku</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>R</given-names>
</string-name>. <article-title>Relative contributions of cystathionine &#x3B2;&#x2010;synthase and &#x3B3;&#x2010;cystathioninase to H<sub>2</sub>S biogenesis via alternative trans&#x2010;sulfuration reactions</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2009</year>;<volume>284</volume>:<fpage>22457</fpage>&#x2010;<lpage>22466</lpage>.<pub-id pub-id-type="pmid">19531479</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0012">
<string-name>
<surname>Yin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>L&#x2010;cysteine metabolism and its nutritional implications</article-title>. <source xml:lang="en">Mol Nutr Food Res</source>. <year>2016</year>;<volume>60</volume>:<fpage>134</fpage>&#x2010;<lpage>146</lpage>.<pub-id pub-id-type="pmid">25929483</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0013">
<string-name>
<surname>Magee</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Richardson</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cummings</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans</article-title>. <source xml:lang="en">Am J Clin Nutr</source>. <year>2000</year>;<volume>72</volume>:<fpage>1488</fpage>&#x2010;<lpage>1494</lpage>.<pub-id pub-id-type="pmid">11101476</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0014">
<string-name>
<surname>Wallace</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Motta</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Buret</surname>
<given-names>AG</given-names>
</string-name>. <article-title>Hydrogen sulfide: an agent of stability at the microbiome&#x2010;mucosa interface</article-title>. <source xml:lang="en">Am J Physiol Gastrointest Liver Physiol</source>. <year>2018</year>;<volume>314</volume>:<fpage>G143</fpage>&#x2010;<lpage>G149</lpage>.<pub-id pub-id-type="pmid">29025733</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0015">
<string-name>
<surname>Libiad</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vitvitsky</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Bostelaar</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Hydrogen sulfide perturbs mitochondrial bioenergetics and triggers metabolic reprogramming in colon cells</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2019</year>;<volume>294</volume>(<issue>13</issue>):<fpage>12077</fpage>&#x2010;<lpage>12090</lpage>.<pub-id pub-id-type="pmid">31213529</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0016">
<string-name>
<surname>Jackson</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Melideo</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Jorns</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Human sulfide:quinone oxidoreductase catalyzes the first step in hydrogen sulfide metabolism and produces a sulfane sulfur metabolite</article-title>. <source xml:lang="en">Biochemistry</source>. <year>2012</year>;<volume>51</volume>:<fpage>6804</fpage>&#x2010;<lpage>6815</lpage>.<pub-id pub-id-type="pmid">22852582</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0017">
<string-name>
<surname>Libiad</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yadav</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Vitvitsky</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Martinov</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>R</given-names>
</string-name>. <article-title>Organization of the human mitochondrial hydrogen sulfide oxidation pathway</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2014</year>;<volume>289</volume>:<fpage>30901</fpage>&#x2010;<lpage>30910</lpage>.<pub-id pub-id-type="pmid">25225291</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0018">
<string-name>
<surname>Landry</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Ballou</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>R</given-names>
</string-name>. <article-title>H<sub>2</sub>S oxidation by nanodisc&#x2010;embedded human sulfide quinone oxidoreductase</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2017</year>;<volume>292</volume>:<fpage>11641</fpage>&#x2010;<lpage>11649</lpage>.<pub-id pub-id-type="pmid">28512131</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0019">
<string-name>
<surname>Rahman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Blok</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Dahl</surname>
<given-names>HH</given-names>
</string-name>, et al. <article-title>Leigh syndrome: clinical features and biochemical and DNA abnormalities</article-title>. <source xml:lang="en">Ann Neurol</source>. <year>1996</year>;<volume>39</volume>(<issue>3</issue>):<fpage>343</fpage>&#x2010;<lpage>351</lpage>.<pub-id pub-id-type="pmid">8602753</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0020">
<string-name>
<surname>Lake</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Compton</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Rahman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Thorburn</surname>
<given-names>DR</given-names>
</string-name>. <article-title>Leigh syndrome: one disorder, more than 75 monogenic causes</article-title>. <source xml:lang="en">Ann Neurol</source>. <year>2016</year>;<volume>79</volume>(<issue>2</issue>):<fpage>190</fpage>&#x2010;<lpage>203</lpage>.<pub-id pub-id-type="pmid">26506407</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0021">
<string-name>
<surname>DiMauro</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Servidei</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zeviani</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Cytochrome c oxidase deficiency in Leigh syndrome</article-title>. <source xml:lang="en">Ann Neurol</source>. <year>1987</year>;<volume>22</volume>:<fpage>498</fpage>&#x2010;<lpage>506</lpage>.<pub-id pub-id-type="pmid">2829705</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0022">
<string-name>
<surname>Karczewski</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Francioli</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Tiao</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Variation across 141,456 human exomes and genomes reveals the spectrum of loss&#x2010;of&#x2010;function intolerance across human protein&#x2010;coding genes</article-title>. <source xml:lang="en">BioRxiv</source>. <year>2019</year>
<pub-id pub-id-type="doi">10.1101/531210</pub-id>
</mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0023">
<string-name>
<surname>Chatfield</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Coughlin</surname>
<given-names>CR</given-names>
<suffix>2nd</suffix>
</string-name>, <string-name>
<surname>Friederich</surname>
<given-names>MW</given-names>
</string-name>, et al. <article-title>Mitochondrial energy failure in HSD10 disease is due to defective mtDNA transcript processing</article-title>. <source xml:lang="en">Mitochondrion</source>. <year>2015</year>;<volume>21</volume>:<fpage>1</fpage>&#x2010;<lpage>10</lpage>.<pub-id pub-id-type="pmid">25575635</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0024">
<string-name>
<surname>Friederich</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Erdogan</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Coughlin</surname>
<given-names>CR</given-names>
<suffix>II</suffix>
</string-name>, et al. <article-title>Mutations in the accessory subunit NDUFB10 result in isolated complex I deficiency and illustrate the critical role of intermembrane space import for complex I holoenzyme assembly</article-title>. <source xml:lang="en">Hum Mol Genet</source>. <year>2017</year>;<volume>26</volume>(<issue>4</issue>):<fpage>702</fpage>&#x2010;<lpage>716</lpage>.<pub-id pub-id-type="pmid">28040730</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0025">
<string-name>
<surname>Maclean</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Greiner</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Stabler</surname>
<given-names>SP</given-names>
</string-name>. <article-title>Long&#x2010;term betaine therapy in a murine model of cystathionine beta&#x2010;synthase deficient homocystinuria: decreased efficacy over time reveals a significant threshold effect between elevated homocysteine and thrombotic risk</article-title>. <source xml:lang="en">Mol Genet Metab</source>. <year>2012</year>;<volume>105</volume>(<issue>3</issue>):<fpage>395</fpage>&#x2010;<lpage>403</lpage>.<pub-id pub-id-type="pmid">22192524</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0026">
<string-name>
<surname>Banerjee</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chiku</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kabil</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Libiad</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Motl</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Parmod</surname>
<given-names>K</given-names>
</string-name>. <article-title>Assay methods for H2S biogenesis and catabolism enzymes</article-title>. <source xml:lang="en">Methods Enzymol</source>. <year>2015</year>;<volume>554</volume>:<fpage>189</fpage>&#x2010;<lpage>200</lpage>.<pub-id pub-id-type="pmid">25725523</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0027">
<string-name>
<surname>Landry</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Moon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>A catalytic trisulfide quinone oxidoreductase catalyzes coenzyme A persulfide synthesis and inhibits butyrate oxidation</article-title>. <source xml:lang="en">Cell Chem Biol</source>. <year>2019</year>;<volume>26</volume>:<fpage>1515</fpage>&#x2010;<lpage>1525</lpage>.<pub-id pub-id-type="pmid">31591036</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="miscellaneous" id="jimd12232-cit-0028">
<collab collab-type="authors">Schr&#xF6;dinger, LLC</collab>
. The PyMOL Molecular Graphics System, Version 2.0, <ext-link ext-link-type="uri" xlink:href="https://pymol.org">https://pymol.org</ext-link>; <year>2019</year>.</mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0029">
<string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Cui</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>LJ</given-names>
</string-name>. <article-title>Comprehensive one&#x2010;step molecular analyses of mitochondrial genome by massively parallel sequencing</article-title>. <source xml:lang="en">Clin Chem</source>. <year>2012</year>;<volume>58</volume>(<issue>9</issue>):<fpage>1322</fpage>&#x2010;<lpage>1331</lpage>.<pub-id pub-id-type="pmid">22777720</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0030">
<string-name>
<surname>Rak</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>B&#xE9;nit</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Chr&#xE9;tien</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Mitochondrial c oxidase deficiency</article-title>. <source xml:lang="en">Clin Sci</source>. <year>2016</year>;<volume>130</volume>(<issue>6</issue>):<fpage>393</fpage>&#x2010;<lpage>407</lpage>.<pub-id pub-id-type="pmid">26846578</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0031">
<string-name>
<surname>Haouzi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sonobe</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Judenherc&#x2010;Haouzi</surname>
<given-names>A</given-names>
</string-name>. <article-title>Developing effective countermeasures against acute hydrogen sulfide intoxication: challenges and limitations</article-title>. <source xml:lang="en">Ann N Y Acad Sci</source>. <year>2016</year>;<volume>1374</volume>:<fpage>29</fpage>&#x2010;<lpage>40</lpage>.<pub-id pub-id-type="pmid">26945701</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0032">
<string-name>
<surname>Vande Weghe</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Ow</surname>
<given-names>DW</given-names>
</string-name>. <article-title>A fission yeast gene for mitochondrial sulfide oxidation</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>1999</year>;<volume>274</volume>:<fpage>13250</fpage>&#x2010;<lpage>13257</lpage>.<pub-id pub-id-type="pmid">10224084</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0033">
<string-name>
<surname>Haouzi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sonobe</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Torsell&#x2010;Tubbs</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Prokopczyk</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Chenuel</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Klingerman</surname>
<given-names>CM</given-names>
</string-name>. <article-title>
<italic>In vivo</italic> interactions between cobalt and ferric compounds and the pools of sulphide in the blood during and after H<sub>2</sub>S poisoning</article-title>. <source xml:lang="en">Toxicol Sci</source>. <year>2014</year>;<volume>141</volume>(<issue>2</issue>):<fpage>493</fpage>&#x2010;<lpage>504</lpage>.<pub-id pub-id-type="pmid">25015662</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0034">
<string-name>
<surname>Bostelaar</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Vitvitsky</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Kumutima</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Hydrogen sulfide oxidation by myoglobin</article-title>. <source xml:lang="en">J Am Chem Soc</source>. <year>2016</year>;<volume>138</volume>(<issue>27</issue>):<fpage>8476</fpage>&#x2010;<lpage>8488</lpage>.<pub-id pub-id-type="pmid">27310035</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0035">
<string-name>
<surname>Ackermann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kubitza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hauska</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pi&#xF1;a</surname>
<given-names>AL</given-names>
</string-name>. <article-title>The vertebrate homologue of sulfide&#x2010;quinone reductase in mammalian mitochondria</article-title>. <source xml:lang="en">Cell Tissue Res</source>. <year>2014</year>;<volume>358</volume>:<fpage>779</fpage>&#x2010;<lpage>792</lpage>.<pub-id pub-id-type="pmid">25130143</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0036">
<string-name>
<surname>Ackermann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kubitza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brawanski</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hauska</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pi&#xF1;a</surname>
<given-names>AL</given-names>
</string-name>. <article-title>The vertebrate homolog of sulfide&#x2010;quinone reductase is expressed in mitochondria of neuronal tissues</article-title>. <source xml:lang="en">Neuroscience</source>. <year>2011</year>;<volume>199</volume>:<fpage>1</fpage>&#x2010;<lpage>12</lpage>.<pub-id pub-id-type="pmid">22067608</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0037">
<string-name>
<surname>Viscomi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Burlina</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Dweikat</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Combined treatment with oral metronidazole and N&#x2010;acetylcysteine is effective in ethylmalonic encephalopathy</article-title>. <source xml:lang="en">Nat Med</source>. <year>2010</year>;<volume>16</volume>(<issue>8</issue>):<fpage>869</fpage>&#x2010;<lpage>871</lpage>.<pub-id pub-id-type="pmid">20657580</pub-id></mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0038">
<string-name>
<surname>Haouzi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Chenuel</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Sonobe</surname>
<given-names>T</given-names>
</string-name>. <article-title>High&#x2010;dose hydroxocobalamin administered after H2S exposure counteracts sulfide&#x2010;poisoning&#x2010;induced cardiac depression in sheep</article-title>. <source xml:lang="en">Clin Toxicol</source>. <year>2015</year>;<volume>53</volume>:<fpage>28</fpage>&#x2010;<lpage>36</lpage>.</mixed-citation>
      </ref>
      <ref id="jimd12232-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal" id="jimd12232-cit-0039">
<string-name>
<surname>Houzi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tubbs</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Chaeung</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Judenher&#x2010;Haouzi</surname>
<given-names>A</given-names>
</string-name>. <article-title>Methylene blue administration during and after life&#x2010;threatening intoxication by hydrogen sulfide: efficacy studies in adult sheep and mechanisms of action</article-title>. <source xml:lang="en">Toxicol Sci</source>. <year>2019</year>;<volume>168</volume>(<issue>2</issue>):<fpage>443</fpage>&#x2010;<lpage>459</lpage>.<pub-id pub-id-type="pmid">30590764</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>